Habib Dable

Habib Dable has over 30 years of experience in the healthcare industry and is currently an advisor at RA Capital Management, L.P. Most recently, Mr. Dable was President and Chief Executive Officer of Acceleron Pharma Inc., a biopharmaceutical company targeting leading-edge therapies for patients with serious and rare diseases, until its acquisition by Merck in 2021. Prior to joining Acceleron in 2016, Mr. Dable spent 22 years at Bayer AG where he served as President of U.S. Pharmaceuticals; Executive Vice President, Global Head Specialty Medicine; Vice President, Ophthalmology; Global Launch Team Head, EYLEA®; Global Head, Neurology and Ophthalmology; and Vice President, Regional Head, Hematology and Cardiology. He serves on the boards of several biotech companies including Atavistik Bio, Tyra Biosciences, SpyGlass Pharma, and PepGen and is a former board member of Blueprint Medicines, Day One Biopharmaceuticals, Millendo Therapeutics, Aerovate Therapeutics, and Albireo Pharma.

Mr. Dable received a B.B.A and M.B.A. from the University of New Brunswick.